Trutakna's Approval and the Deepening Science of IgA Nephropathy

On July 7, 2026, the FDA granted accelerated approval to Trutakna (atacicept-vymj), a subcutaneous injection developed by Vera Therapeutics, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. The approval is notable not just for the patients it reaches, but for what it signals about how the scientific community has come to understand a disease that was, for most of its clinical history, treated with blunt instruments and incomplete theories.

IgA nephropathy is the most common primary glomerulonephritis worldwide. It affects an estimated 150,000 people in the United States and millions more globally, with a disproportionate burden in Asian populations. The disease is caused by an abnormal form of immunoglobulin A that accumulates in the kidneys, triggering inflammation and progressive damage. Over time, that damage can lead to kidney failure. For decades, the treatment toolkit consisted largely of blood pressure control, renin-angiotensin system blockade, and in some cases corticosteroids, none of which addressed the underlying immunological mechanism driving the disease.

What Makes Trutakna Different

Trutakna is a soluble recombinant fusion protein that contains the native human TACI receptor, which binds to two cytokines: B-cell activating factor (BAFF) and A Proliferation-Inducing Ligand (APRIL). These cytokines promote the survival and maturation of B cells, the immune cells responsible for producing the abnormal IgA antibodies that accumulate in the kidneys. By blocking both BAFF and APRIL simultaneously, Trutakna targets the disease at its immunological source rather than managing its downstream consequences.

That dual mechanism is what distinguishes Trutakna from the other approved therapies in the IgA nephropathy space. Tarpeyo (budesonide) works through broad anti-inflammatory action in the gut-associated lymphoid tissue. Filspari (sparsentan) combines endothelin receptor antagonism with angiotensin receptor blockade to reduce proteinuria through hemodynamic and anti-fibrotic pathways. Fabhalta (iptacopan) targets complement factor B, addressing the complement cascade that amplifies kidney injury downstream of the initial IgA deposition. Each of these mechanisms is scientifically valid, but none of them directly suppresses the B-cell activity that produces the pathological IgA in the first place. Trutakna does.

The clinical data supporting the approval come from the ORIGIN 3 Phase 3 trial. In a prespecified interim analysis of the first 203 patients who reached the nine-month visit, those treated with Trutakna achieved an average 46% reduction in proteinuria compared to placebo. The trial continues in a blinded, placebo-controlled manner to evaluate the effect on kidney function as measured by estimated glomerular filtration rate, with results expected in the third quarter of 2026. Pending those results, Vera Therapeutics plans to submit a supplemental biologics license application for full approval in the fourth quarter of 2026.

The Accelerated Approval Question

The FDA granted Trutakna accelerated approval based on proteinuria reduction as a surrogate endpoint. The agency has not yet established whether Trutakna slows kidney function decline over the long term, and continued approval is contingent on the confirmatory eGFR data from ORIGIN 3. This is a familiar structure in nephrology, where proteinuria is a well-validated surrogate for kidney disease progression but is not itself the clinical outcome that matters most to patients.

The use of accelerated approval here reflects a broader shift in how the FDA has approached kidney disease over the past several years. The agency has been willing to accept proteinuria reduction as a basis for approval in IgA nephropathy, recognizing that the disease progresses slowly and that waiting for hard kidney function endpoints would delay access to potentially meaningful therapies by years. That approach has enabled a wave of approvals in the space, but it also means that the field is accumulating a portfolio of drugs whose long-term effects on kidney survival remain to be fully established. The ORIGIN 3 eGFR data, when they arrive, will be among the most closely watched readouts in nephrology this year.

A Crowded Field With Genuine Differentiation

The IgA nephropathy treatment landscape has transformed remarkably quickly. Three years ago, there were no approved therapies specifically targeting the disease mechanism. Today there are four, with Trutakna joining Tarpeyo, Filspari, and Fabhalta. The global market for IgA nephropathy treatments, estimated at roughly $525 million in 2025, is projected to reach nearly $2.7 billion by 2033 as the approved drug portfolio expands and diagnosis rates improve.

That growth projection reflects both the commercial opportunity and the genuine unmet need. IgA nephropathy is chronically underdiagnosed, in part because it requires a kidney biopsy for definitive diagnosis and in part because its early stages are often asymptomatic. Many patients are not identified until significant kidney damage has already occurred. As awareness grows and diagnostic practices improve, the addressable population for these therapies is likely to expand considerably beyond current estimates.

The question of how these four drugs will be sequenced and combined in clinical practice is one that nephrologists are only beginning to work through. Each targets a different point in the disease pathway, which raises the possibility of rational combination strategies that address multiple mechanisms simultaneously. Vera Therapeutics has already indicated that it is exploring atacicept in combination with other agents, and the ORIGIN program includes studies in expanded populations including membranous nephropathy and focal segmental glomerulosclerosis. The TACI receptor that Trutakna targets is expressed in multiple B-cell-mediated diseases, and the company's pipeline reflects an ambition to build a broader franchise around the same mechanism.

What the Approval Means for Vera Therapeutics

For Vera Therapeutics, a Brisbane, California-based biotech that has been developing atacicept since its founding, the approval represents the culmination of a clinical program that has been in development for years and has been administered to more than 1,500 patients across multiple disease areas. The company retains all global developmental and commercial rights to atacicept, which is an unusual position for a small biotech with a late-stage asset in a competitive market. It means that the commercial upside, if the drug performs well, accrues entirely to Vera rather than being shared with a larger partner. It also means that the commercial execution risk sits entirely with Vera, a company that has not previously launched a product.

The company has indicated it plans a US commercial launch in mid-2026, and it has established a patient support program to help navigate insurance coverage and financial assistance. The pricing and reimbursement dynamics in the IgA nephropathy space will be shaped by the presence of multiple approved agents, each with its own clinical profile and commercial infrastructure. Vera's ability to differentiate Trutakna on the basis of its upstream B-cell mechanism, its once-weekly subcutaneous self-administration, and its Breakthrough Therapy designation will be central to how it positions the drug against established competitors.

The Longer Arc

The approval of Trutakna is a meaningful moment in the history of IgA nephropathy treatment, but it is also a waypoint rather than a destination. The confirmatory eGFR data from ORIGIN 3 will determine whether the proteinuria reduction seen in the trial translates into the kidney function preservation that patients and physicians ultimately care about. The combination strategies that are beginning to be explored will take years to generate the evidence needed to change clinical practice. And the diagnostic gap that leaves many patients unidentified until late in their disease course remains a structural challenge that no drug approval can solve on its own.

What the approval does establish is that the BAFF/APRIL pathway is a clinically validated target in IgA nephropathy, that blocking it produces meaningful reductions in the protein leakage that marks kidney damage, and that the FDA is willing to act on that evidence while the longer-term data mature. For a disease that spent decades without a single approved therapy targeting its mechanism, that is a substantial change in the landscape. The harder work of translating that change into preserved kidney function for the patients who need it most is the work that the next several years of data will determine.